Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer
暂无分享,去创建一个
[1] Yang Xu,et al. The gain of function of p53 cancer mutant in promoting mammary tumorigenesis , 2013, Oncogene.
[2] D. Walerych,et al. The rebel angel: mutant p53 as the driving oncogene in breast cancer , 2012, Carcinogenesis.
[3] L. Gu,et al. MDM2 Regulates Vascular Endothelial Growth Factor mRNA Stabilization in Hypoxia , 2011, Molecular and Cellular Biology.
[4] Eugene S. Kim,et al. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma , 2011, Angiogenesis.
[5] F. Westermann,et al. Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3 , 2011, Molecular Cancer Therapeutics.
[6] M. Saha,et al. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity , 2010, Cancer biology & therapy.
[7] F. Speleman,et al. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. , 2009, Journal of the National Cancer Institute.
[8] L. Huang,et al. Nutlin-3, an Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1alpha. , 2009, Carcinogenesis.
[9] D. Durden,et al. Regulation of XIAP translation and induction by MDM2 following irradiation. , 2009, Cancer cell.
[10] M. Raffeld,et al. MDM2 Antagonist Nutlin-3 Displays Antiproliferative and Proapoptotic Activity in Mantle Cell Lymphoma , 2009, Clinical Cancer Research.
[11] I. Kasman,et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. , 2009, Cancer cell.
[12] E. Perez,et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Shaomeng Wang,et al. Targeting the MDM2-p53 Interaction for Cancer Therapy , 2008, Clinical Cancer Research.
[14] B. K. Park,et al. MDM2 regulates dihydrofolate reductase activity through monoubiquitination. , 2008, Cancer research.
[15] Jing Wang,et al. Evaluation of biological pathways involved in chemotherapy response in breast cancer , 2008, Breast Cancer Research.
[16] H. Findley,et al. MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2 , 2008, Leukemia.
[17] M. Ashcroft,et al. Regulation of angiogenic factors by HDM2 in renal cell carcinoma. , 2008, Cancer research.
[18] K. Phoenix,et al. Double-Stranded RNA-Binding Protein Regulates Vascular Endothelial Growth Factor mRNA Stability, Translation, and Breast Cancer Angiogenesis , 2007, Molecular and Cellular Biology.
[19] L. Mayo,et al. Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2. , 2007, Cancer research.
[20] F. Agani,et al. Mdm2 and HIF‐1α interaction in tumor cells during hypoxia , 2005 .
[21] Hui Wang,et al. Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms. , 2005, Current cancer drug targets.
[22] Ruiwen Zhang,et al. p53-independent activities of MDM2 and their relevance to cancer therapy. , 2005, Current cancer drug targets.
[23] G. Tortora,et al. Combined Targeting of Epidermal Growth Factor Receptor and MDM2 by Gefitinib and Antisense MDM2 Cooperatively Inhibit Hormone-Independent Prostate Cancer , 2004, Clinical Cancer Research.
[24] R. Hill,et al. Hypoxia Enhances Metastatic Efficiency by Up-Regulating Mdm2 in KHT Cells and Increasing Resistance to Apoptosis , 2004, Cancer Research.
[25] Hui Wang,et al. Radiosensitization by Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in in Vitro and in Vivo Human Cancer Models , 2004, Clinical Cancer Research.
[26] L. Vassilev,et al. In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.
[27] P. Chène. Inhibiting the p53–MDM2 interaction: an important target for cancer therapy , 2003, Nature Reviews Cancer.
[28] A. Levy,et al. A 40-bp RNA Element That Mediates Stabilization of Vascular Endothelial Growth Factor mRNA by HuR* , 2002, The Journal of Biological Chemistry.
[29] Moshe Oren,et al. The p53 and Mdm2 families in cancer. , 2002, Current opinion in genetics & development.
[30] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[31] Hui Wang,et al. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[32] K. Claffey,et al. Regulation of Human Vascular Endothelial Growth Factor mRNA Stability in Hypoxia by Heterogeneous Nuclear Ribonucleoprotein L* , 1999, The Journal of Biological Chemistry.
[33] A. Sendelhofert,et al. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. , 1998, The American journal of pathology.
[34] S. Agrawal,et al. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[35] M. Goldberg,et al. Post-transcriptional Regulation of Vascular Endothelial Growth Factor by Hypoxia (*) , 1996, The Journal of Biological Chemistry.
[36] A. Logan,et al. Angiogenesis , 1993, The Lancet.
[37] C. Theillet,et al. p53 mutations occur in aggressive breast cancer. , 1992, Cancer research.
[38] A. Levine,et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.
[39] L. Vassilev,et al. MDM2 inhibitors for cancer therapy. , 2007, Trends in molecular medicine.
[40] T. Nielsen,et al. MDM2 protein expression is a negative prognostic marker in breast carcinoma , 2006, Modern Pathology.
[41] F. Agani,et al. Mdm2 and HIF-1alpha interaction in tumor cells during hypoxia. , 2005, Journal of cellular physiology.
[42] W. Gu,et al. Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function. , 2003, The Journal of biological chemistry.
[43] R. Ralhan,et al. Alterations in p53 and pRb pathways and their prognostic significance in oesophageal cancer. , 2002, European journal of cancer.